XORTX Therapeutics Inc. - What You Need to Know

Thinking about investing in XORTX Therapeutics? Getting in early on a biotech company is exciting, but it can be a wild ride. Here is a plain-English breakdown of what you are looking at based on their latest updates.

1. What does this company do?

XORTX is a "clinical-stage" biotech company. Simply put, they are scientists working to turn research into medicine. Their main goal is to fix a specific problem: too much uric acid in the body.

They are focusing on their lead program, XORLO™. They believe it will be a game-changer for patients who cannot take standard gout medications. They estimate this market could be worth $700 million per year. Beyond gout, they are testing their drugs to treat kidney disease linked to ADPKD and other rare conditions.

2. How do they make money?

They don’t make money yet. Like many biotech firms, they spend cash on tests and trials instead of generating sales. They have never paid a dividend (a share of profits to investors) and do not plan to anytime soon. Their "growth" is measured by how successfully they move drugs through the FDA approval process. Because they have no products to sell, they rely entirely on raising money through selling shares or taking on debt to survive.

3. What is the current financial situation?

XORTX is raising money to keep research going, but there are hurdles:

• The New Offering: As of late 2025, they are raising about $3.8 million by selling new shares and "warrants" (coupons that allow investors to buy more stock later).
• The "Dilution" Factor: This offering will cause "dilution." Because they are creating and selling millions of new shares, your ownership percentage in the company shrinks. New investors will pay $0.84 per share, but the actual value of the company’s assets per share is lower. This leads to an immediate drop in value per share for new buyers.
• Nasdaq Warning: Their share price has traded below the $1.00 minimum required by the Nasdaq. If the price stays low, they could be "de-listed." This would make the stock harder to trade and hurt their ability to raise money.
• Management Control: Management has "broad discretion" over the money they raise. They decide how to spend those millions on trials and research without needing your permission for every move.

4. What are the main risks?

• The "All or Nothing" Risk: If the FDA does not approve their drugs, or if trials fail, the company has nothing to sell. In this case, the company’s value could collapse.
• Volatility: The stock price can swing wildly based on trial results or market trends.
• Warrant Value: The new warrants have no public market. If the stock price stays below the "exercise price," they will expire worthless.
• Capital Dependency: The company consistently loses money. They will need significant additional funding to finish developing their products.

5. Where does it trade?

You can find them on the NASDAQ and the TSXV under the symbol XRTX.

A final piece of advice: Investing in a company without sales is a bet on the future. Before you buy, ask yourself if you are comfortable with the high risk of losing your principal investment. If you decide to move forward, keep this as just one small piece of a larger, diversified portfolio.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and does not constitute financial advice. Always do your own research or consult with a professional before investing.